This federal contract award, identified as SPE2DP20D0002|SPE2DP24F6271, was issued by the Defense Logistics Agency (DLA) Troop Support Medical to Teva Pharmaceuticals USA, Inc., a foreign-owned, for-profit pharmaceutical manufacturer. The contract, valued at $158,804.73, is for the delivery of Adenovirus Type 4 vaccine, a critical product supporting military immunization programs. This is a Firm Fixed Price Delivery Order contract, with a period of performance through July 30, 2024. The contract does not have a set-aside designation, as Teva competes as a large business in unrestricted solicitations. Teva Pharmaceuticals USA, Inc. holds several significant Indefinite Delivery Contracts (IDCs) with federal agencies, including the Department of Veterans Affairs (VA), Department of Defense (DOD), Bureau of Prisons, and Indian Health Service, demonstrating its crucial role in maintaining pharmaceutical supplies for federal healthcare programs.
Generated 10/18/24, 9:08 AM